Economic impact of using clodronate in the management of patients with multiple myeloma

British Journal of Haematology

Volumn 104, Issue 2, 1999, Pages 358-364

  Bruce, N J ^a   McCloskey, E V ^b   Kanis, J A ^b   Guest, J F ^a  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Clodronate; Costs; Multiple myeloma; Resources

Indexed keywords

CLODRONIC ACID;

ARTICLE; CANCER CHEMOTHERAPY; DRUG COST; ECONOMIC EVALUATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

CLODRONIC ACID; COST-BENEFIT ANALYSIS; DRUG COSTS; FRACTURES, BONE; HEALTH RESOURCES; HUMANS; MULTIPLE MYELOMA; RECURRENCE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 0032956189     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01194.x     Document Type: Article

References (19)

1. Adami, S. & Mian, M. (1989) Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results in Cancer Research, Bisphosphonates and Tumour Osteolysis. 116, 67-72.
2. Bataille, R., Chappard, D. & Klein, B. (1992) Mechanisms of bone lesions in multiple myeloma. Haematology/Oncology Clinics of North America, 6, 285-295.
3. Biermann, W.A., Cantor, R.I., Fellin, F.M., Jakobowski, J., Hopkins, L. & Newbold, R.C., III (1991) An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone, 12, (Suppl. 1), S37-S42.
4. Chartered Institute of Public Finance and Accountancy (CIPFA) (1996) Health Database. London.
5. Ernst, D.S., MacDonald, R.N., Alexander, H.G., Paterson, A.H.G., Jensen, J., Brasher, P. & Bruera, E. (1992) A double-blind cross-over trial of intravenous clodronate in metastatic bone pain. Journal of Pain and Symptom Management, 7, 4-11.
6. Fleisch, H. (1995) Bisphosphonates in Bone Disease: from the Laboratory to the Patient, 2nd edn. The Parthenon Publishing Group, London.
7. Guest, J.F., Boyd, O., Hart, W.M., Grounds, R.M. & Bennett, E.D., (1997) A cost analysis of a treatment policy of a deliberate perioperative increase in oxygen delivery in high-risk surgical patients. Intensive Care Medicine, 23, 85-90.
8. Guest, J.F., Hart, W.M. & Cookson, R.F. (1998a) Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. PharmacoEconomics, 14, 285-297.
9. Guest, J.F., Munro, V. & Cookson, R.F. (1998b) The annual cost of blood transfusions in the United Kingdom. Clinical Laboratory Medicine, 20, 111-118.
10. Kanis, J.A., Powles, T., Paterson, A.H.G., McCloskey, E.V. & Ashley, S. (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone, 19, 663-667.
11. Laakso, M., Lahtinen, R., Virkkunen, P. & Elomaa, I. (1994) Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. British Journal of Haematology, 87, 725-729.
12. Lahtinen, R., Laakso, M., Palva, I., Virkkunen, P. & Elomma, I. (1992) Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet, 340, 1049-1052.
13. McCloskey, E.V., MacLennan, I.C.M., Drayson, M.T., Chapman, C., Dunn, J. & Kanis, J.A., for the MRC Working Party on Leukaemia in Adults (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology, 100, 317-325.
14. Monthly Index of Medical Specialities (MIMS) (1997) January 1997 edition. Haymarket Publications Ltd, London.
15. Netten, A. & Dennett, J. (1996) Unit Costs of Health and Social Care 1996. Personal Social Services Research Unit, University of Kent, Canterbury.
16. O'Rourke, N.P., McCloskey, E.V., Vasikaran, S., Eyres, K., Fern, D. & Kanis, J.A. (1993) Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. British Journal of Cancer, 67, 560-563.
17. Paterson, A.H.G., Powles, T.J., Kanis, J.A., McCloskey, E.V., Hanson, J. & Ashley, S. (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology, 11, 59-65.
18. Taube, T., Beneton, M.N.C., McCloskey, E.V., Rogers, S., Greaves, M. & Kanis, J.A. (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resportion. European Journal of Haematology, 49, 192-198.
19. Valentin-Opran, A., Charhon, S.A., Meunier, P.J., Edouard, C.M. & Arlot, M.E. (1982) Quantitative histology of myeloma-induced bone changes. British Journal of Haematology, 52, 601-610.